Motilium® (domperidone): New recommendations to minimise cardiac risks

Kadar pengguna: 1 / 5

bintang aktifBintang tidak aktifBintang tidak aktifBintang tidak aktifBintang tidak aktif

Date: 4 August 2015


The NPCB would like to alert healthcare professionals of restrictions to the use of domperidone to minimise the risk of cardiac adverse effects. The indication of domperidone has been tightened, the maximum daily dose restricted to 40mg/day, and new contraindications have been added.Domperidone should be used at the lowest effective dose for the shortest possible duration. The DCAhas issued a directive for all products containing domperidone to update their package inserts with information regarding this safety issue. For further details, please refer to the Direct Healthcare Professional Communication (DHPC) issued by Janssen, a division of Johnson & Johnson Sdn. Bhd., in agreement with NPCB.


National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400




The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Site Last Modified

  • Last Modified: Selasa 16 Julai 2024, 09:30:33.
© Copyright 2018 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA


Menu Utama